Low-dose 2-deoxy glucose stabilises tolerogenic dendritic cells and generates potent in vivo immunosuppressive effects

Cell therapies for autoimmune diseases using tolerogenic dendritic cells (tolDC) have been promisingly explored. A major stumbling block has been generating stable tolDC, with low risk of converting to mature immunogenic DC (mDC), exacerbating disease. mDC induction involves a metabolic shift to lac...

Descripción completa

Detalles Bibliográficos
Autores principales: Christofi, M., Le Sommer, S., Mölzer, C., Klaska, I. P., Kuffova, L., Forrester, J. V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8004500/
https://www.ncbi.nlm.nih.gov/pubmed/33074350
http://dx.doi.org/10.1007/s00018-020-03672-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8004500/
https://www.ncbi.nlm.nih.gov/pubmed/33074350
http://dx.doi.org/10.1007/s00018-020-03672-y

Ejemplares similares